MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 04-25-2026
Akari Therapeutics, Plc Total Non Current Liabilities 2011-2026 | AKTX
Annual Total Non Current Liabilities Akari Therapeutics, Plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | 50 K | 60 K | 50 K | 268 K | 787 K | 630 K | 276 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 787 K | 50 K | 303 K |
Quarterly Total Non Current Liabilities Akari Therapeutics, Plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 213 K | - | 48 K | - | 58 K | - | 56.4 K | - | 55.1 K | 52.1 K | 49.1 K | 46 K | 1.03 M | 49.1 K | - | - | 268 K | 268 K | 787 K | - | - | - | 630 K | - | - | - | 276 K | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.03 M | 46 K | 259 K |
Total Non Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 21.81 | 1.87 % | $ 1.02 B |  USA |
 |
I-Mab
IMAB
|
131 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
2.21 M | $ 0.91 | 1.61 % | $ 6.69 M | China |
 |
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
49.6 M | $ 22.56 | 2.73 % | $ 3.74 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
355 M | $ 1.97 | 3.14 % | $ 409 M | USA |
 |
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | USA |
 |
Galectin Therapeutics
GALT
|
52 K | $ 2.43 | 4.29 % | $ 155 M | USA |
 |
Greenwich LifeSciences
GLSI
|
9.5 M | $ 24.22 | 0.04 % | $ 315 M | USA |
 |
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M | USA |
 |
Heron Therapeutics
HRTX
|
14.6 M | $ 1.21 | 1.26 % | $ 202 M | USA |
 |
ImmuCell Corporation
ICCC
|
11.5 M | $ 8.22 | -1.56 % | $ 74.2 M | USA |
 |
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | USA |
 |
InflaRx N.V.
IFRX
|
254 K | $ 1.61 | 8.78 % | $ 152 M | Germany |
 |
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.53 M | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - |  Russia |
 |
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | USA |
 |
Innate Pharma S.A.
IPHA
|
105 M | $ 1.4 | -1.06 % | $ 235 M | France |
 |
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
618 K | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | USA |
 |
Inventiva S.A.
IVA
|
13.8 M | $ 5.07 | -1.65 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
10.3 M | $ 0.34 | -13.72 % | $ 793 K | USA |
 |
Aridis Pharmaceuticals
ARDS
|
854 K | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
341 M | $ 102.66 | -2.66 % | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
5.05 M | $ 19.68 | 0.25 % | $ 1.06 B | Britain |
 |
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.12 | 0.86 % | $ 441 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
167 M | $ 23.45 | 0.82 % | $ 2.98 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.44 | -0.35 % | $ 383 M | Britain |
 |
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
30.8 B | - | - | $ 96.9 B | Britain |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
711 M | $ 232.91 | 0.71 % | $ 4.26 B | USA |
 |
AVROBIO
AVRO
|
276 K | - | 1083.1 % | $ 745 M | USA |
 |
Eli Lilly and Company
LLY
|
50.7 B | $ 880.24 | -0.42 % | $ 790 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 2.92 | -0.34 % | $ 4.81 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | USA |